These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15489838)

  • 1. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fenofibrate].
    Yamashita T; Nakamura H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():618-24. PubMed ID: 11347142
    [No Abstract]   [Full Text] [Related]  

  • 3. Implications of 4S evidence on baseline lipid levels.
    Durrington PN
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
    [No Abstract]   [Full Text] [Related]  

  • 4. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
    Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
    Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia.
    Kusunoki M; Sato D; Tsutsumi K; Tsutsui H; Nakamura T; Oshida Y
    J Med Food; 2015 Jun; 18(6):615-8. PubMed ID: 25651043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates and homocysteine.
    Young IS; Woodside JV
    Nutrition; 2001; 17(11-12):973-4. PubMed ID: 11744353
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of 4S evidence on baseline lipid levels.
    Ravnskov U
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
    [No Abstract]   [Full Text] [Related]  

  • 8. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
    Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
    Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
    Ansquer JC; Foucher C; Rattier S; Taskinen MR; Steiner G;
    Am J Kidney Dis; 2005 Mar; 45(3):485-93. PubMed ID: 15754270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
    Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
    Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 13. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
    Krysiak R; Gilowski W; Okopien B
    Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid-lowering drugs and homocysteine.
    de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G
    Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
    Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
    Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract]   [Full Text] [Related]  

  • 19. [Helsinki Heart Study].
    Sekiya M; Ishibashi S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.
    Playford DA; Watts GF; Best JD; Burke V
    Am J Cardiol; 2002 Dec; 90(11):1254-7. PubMed ID: 12450611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.